Gerry Smith is a Reporter at Bloomberg. He specializes in the fields of medicine and healthcare, focusing on topics such as pharmaceuticals, healthcare technology, and alternative medicine. Gerry's work has been featured in numerous respected publications, including Bloomberg-Quint, Fortune, and The Los Angeles Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gerry Smith's coverage is primarily focused on healthcare and pharmaceuticals, with a significant emphasis on press releases and data citations. When reaching out to Gerry, consider offering access to exclusive data or insights related to the latest developments in biotech, pharmaceuticals, gene editing, vaccines, and other healthcare-related topics.
As he also covers sports but at a lower percentage compared to healthcare & pharmaceuticals, it may be beneficial for pitches related to sports topics within the context of health and wellness. However, given that only 28% of his articles are about sports topics while 40% are about healthcare & pharmaceuticals; focusing primarily on providing valuable insights into health-related themes would likely yield more success when pitching him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Gerry Smith, Rachel Cohrs Zhang
Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel next month, a sign that the agency may be increasing transparency into its decision-making after several controversies.
By: Gerry Smith, Rachel Cohrs Zhang
Moderna Inc.'s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel next month, a sign
By: Madison Muller, Gerry Smith
Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise.
By: Madison Muller, Gerry Smith
Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise.
By: Gerry Smith, Madison Muller
In recent weeks, Lilly has pledged to shell out up to $7.8 billion for sleep drugmaker Centessa Pharmaceuticals Plc and up to $7 billion for cancer
By: Madison Muller, Gerry Smith
Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise.
Blackstone Inc. is providing as much as $1.3 billion in financing to Apogee Therapeutics Inc. to help the biotech company advance a potential competitor to the blockbuster drug Dupixent.
By: Michelle Fay Cortez, Gerry Smith
Drugs in development to treat and prevent infections caused by the Ebola virus that’s circulating in the Democratic Republic of Congo and Uganda
By: Gerry Smith, Emily Chang
The founder of 23andMe Research Institute wants to reach 100 million users, an ambitious goal after the seller of DNA testing kits emerged from bankruptcy as a nonprofit.
By: Gerry Smith, Emily Chang
The founder of 23andMe Research Institute wants to reach 100 million users, an ambitious goal after the seller of DNA testing kits emerged from bankruptcy as a nonprofit. 23andMe has the DNA of about 13 million users who mailed in saliva samples in exchange for data about their genetic code.
